A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson's Disease Arising from Parkin Mutations.
Dunhui LiMay Thandar Aung-HtutKristin A HamSusan FletcherSteve D WiltonPublished in: International journal of molecular sciences (2020)
Parkin-type autosomal recessive juvenile-onset Parkinson's disease is caused by mutations in the PRKN gene and accounts for 50% of all autosomal recessive Parkinsonism cases. Parkin is a neuroprotective protein that has dual functions as an E3 ligase in the ubiquitin-proteasome system and as a transcriptional repressor of p53. While genomic deletions of PRKN exon 3 disrupt the mRNA reading frame and result in the loss of functional parkin protein, deletions of both exon 3 and 4 maintain the reading frame and are associated with a later onset, milder disease progression, indicating this particular isoform retains some function. Here, we describe in vitro evaluation of antisense oligomers that restore functional parkin expression in cells derived from a Parkinson's patient carrying a heterozygous PRKN exon 3 deletion, by inducing exon 4 skipping to correct the reading frame. We show that the induced PRKN transcript is translated into a shorter but semi-functional parkin isoform able to be recruited to depolarised mitochondria, and also transcriptionally represses p53 expression. These results support the potential use of antisense oligomers as a disease-modifying treatment for selected pathogenic PRKN mutations.
Keyphrases
- binding protein
- poor prognosis
- working memory
- intellectual disability
- induced apoptosis
- randomized controlled trial
- early onset
- gene expression
- muscular dystrophy
- protein protein
- case report
- signaling pathway
- drug induced
- dna methylation
- high glucose
- autism spectrum disorder
- reactive oxygen species
- combination therapy
- genome wide
- nucleic acid
- brain injury
- climate change